BioPharm International Supplements, January 2009 - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

BioPharm International Supplements, January 2009
Articles
The Therapeutic Vaccine Potential of MIS416 Adjuvant
By Gill A. Webster, PhD , Frank B. Gelder, PhD
This article discusses the potential of MIS416 adjuvant, a vaccine adjuvant and immunogen co-delivery system, to provide adequate immunostimulation to overcome host factors that may limit the success of therapeutic vaccines.
An Alternative to the Scale-up and Distribution of Pandemic Flu Vaccine
By James M. Robinson
With virus-based production, vaccines can be available in 10-12 weeks.
Advances in Single-Shot Vaccine Development
By Bas Kremer, PhD , Rianne Roukema , Leo de Leede
The disadvantages of the traditional vaccine regime (prime plus boost) have spurred the development of single-shot vaccines. This article describes the development and manufacture of a prototype single-shot vaccine that uses microspheres made from cross-linked modified dextran polymers for controlled release of the antigen.
Advertisers in This Issue
Boehringer Ingelheim Corporation
Grenier Bio One
GE Healthcare
Baxter Healthcare
WuXi Apptech

ADVERTISEMENT

ADVERTISEMENT

Click here